(UroToday.com) Beginning with the introduction of docetaxel for metastatic castration resistant prostate cancer (mCRPC) in 2004, there has been a dramatic and rapid proliferation of systemic therapy options in advanced prostate cancer including a number of novel hormonal therapies (including abiraterone acetate and enzalutamide), second-line chemotherapy (cabazitaxel), bone-targeting agents (radium-223) and other targeted agents (including olaparib, rucaparib, and pembrolizumab), each of which has proven survival benefits. Recently, theranostic treatment with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy, including most notably 177lutetium-PSMA-617 as well as others, has demonstrated promising activity among pre-treated individuals with mCRPC. However, most patients develop progression following treatment with 177lutetium-PSMA-617. One treatment option for these patients is further radionuclide therapy with 225Ac-PSMA-617 targeted alpha therapy. In the Cancer Radiopharmaceutical Therapy session at the 2021 Society of Nuclear Medicine & Molecular Imaging Annual Meeting, Dr. Madhav Yadav presented an assessment of the safety and therapeutic efficacy of 225Ac-PSMA-617 targeted alpha therapy in patients with mCRPC.